meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
atezolizumab plus cabozantinib
camrelizumab based treatment
durvalumab based treatment
durvalumab plus bevacizumab
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab plus lenvatinib
sintilimab based treatment
sintilimab
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab
versus all
vs non active control
vs placebo
vs VEGF(R) inhibitor
vs lenvatinib
vs sorafenib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded